Humanwell Healthcare (600079.SH): HW201877 capsules received the notification of approval for clinical drug trials.

Humanwell Healthcare (600079.SH) announced that its wholly-owned subsidiary, Wuhan Renfu Innovation Drug Development Center Co., Ltd. (referred to as "Innovation Drug Development Center"), has recently received the Drug Clinical Trial Approval Notice for HW201877 Capsules issued by the National Medical Products Administration. The indication applied for is inflammatory bowel disease. HW201877 Capsules are intended for clinical use in patients with inflammatory bowel disease. Currently, there are no similar products on the market in China. As of now, the cumulative research and development investment in this project by the Innovation Drug Development Center is approximately 40 million RMB.